Enhanced Chemotherapeutic Efficacy of Paclitaxel Nanoparticles Co-delivered with MicroRNA-7 by Inhibiting Paclitaxel-Induced EGFR/ERK pathway Activation for Ovarian Cancer Therapy

2018 ◽  
Vol 10 (9) ◽  
pp. 7821-7831 ◽  
Author(s):  
Xiaojuan Cui ◽  
Ying Sun ◽  
Ming Shen ◽  
Keqi Song ◽  
Xia Yin ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Therapy ◽  
Erk Pathway ◽  
Chemotherapeutic Efficacy ◽  
Pathway Activation

Enterovirus 71 induces autophagy in mice via mTOR inhibition and ERK pathway activation

Life Sciences ◽  
2021 ◽  
Vol 271 ◽  
pp. 119188
Author(s):  
Baixin Wang ◽  
Yuanzhi Zhu ◽  
Lei Liu ◽  
Binshan Wang ◽  
Mei Chen ◽  
...  
Keyword(s):  
Enterovirus 71 ◽  
Erk Pathway ◽  
Mtor Inhibition ◽  
Pathway Activation

Antineoplastic nano-lipobubbles for passively targeted ovarian cancer therapy

2019 ◽  
Vol 177 ◽  
pp. 160-168 ◽  
Author(s):  
Derusha Frank ◽  
Sunaina Indermun ◽  
Mershen Govender ◽  
Pradeep Kumar ◽  
Yahya E. Choonara ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Therapy

scholarly journals Dasatinib (BMS-35482) Interacts Synergistically With Docetaxel, Gemcitabine, Topotecan, and Doxorubicin in Ovarian Cancer Cells With High SRC Pathway Activation and Protein Expression

2014 ◽  
Vol 24 (2) ◽  
pp. 218-225 ◽  
Author(s):  
Angeles Alvarez Secord ◽  
Deanna Teoh ◽  
Jingquan Jia ◽  
Andrew B. Nixon ◽  
Lisa Grace ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Protein Expression ◽  
Cancer Cells ◽  
Combination Index ◽  
Chemotherapeutic Agents ◽  
Cytotoxic Agents ◽  
Ovarian Cancer Cells ◽  
Response Curves ◽  
Pathway Activation ◽  
Skov3 Cells

PurposeThis study aimed to explore the activity of dasatinib in combination with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells.MethodsCells with previously determined SRC pathway and protein expression (SRC pathway/SRC protein IGROV1, both high; SKOV3, both low) were treated with dasatinib in combination with the cytotoxic agents. SRC and paxillin protein expression were determined pretreatment and posttreatment. Dose-response curves were constructed, and the combination index (CI) for drug interaction was calculated.ResultsIn the IGROV1 cells, dasatinib alone reduced phospho-SRC/total SRC 71% and p-paxillin/t-paxillin ratios 77%. Phospho-SRC (3%–33%; P = 0.002 to 0.04) and p-paxicillin (6%–19%; P = 0.01 to 0.05) levels were significantly reduced with dasatinib in combination with each cytotoxic agent. The combination of dasatinib and docetaxel, gemcitabine, or topotecan had a synergistic antiproliferative effect (CI, 0.49–0.68), whereas dasatinib combined with doxorubicin had an additive effect (CI, 1.08).In SKOV3 cells, dasatinib resulted in less pronounced reductions of phospho-SRC/total SRC (49%) and p-paxillin/t-paxillin (62%). Phospho-SRC (18%; P < 0.001) and p-paxillin levels (18%; P = 0.001; 9%; P = 0.007) were significantly decreased when dasatinib was combined with docetaxel and topotecan (p-paxillin only). Furthermore, dasatinib combined with the cytotoxics in the SKOV3 cells produced an antagonistic interaction on the proliferation of these cells (CI, 1.49–2.27).ConclusionsDasatinib in combination with relapse chemotherapeutic agents seems to interact in a synergistic or additive manner in cells with high SRC pathway activation and protein expression. Further evaluation of dasatinib in combination with chemotherapy in ovarian cancer animal models and exploration of the use of biomarkers to direct therapy are warranted.

Application in Gene Editing in Ovarian Cancer Therapy

2021 ◽  
pp. 1-13
Author(s):  
Shuang Luo ◽  
Yujiao Wang ◽  
Yongyu Tao ◽  
Shuo Li ◽  
Zirui Wang ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Therapy ◽  
Gene Editing

scholarly journals E-cadherin promotes proliferation of human ovarian cancer cells in vitro via activating MEK/ERK pathway

2012 ◽  
Vol 33 (6) ◽  
pp. 817-822 ◽  
Author(s):  
Ling-ling Dong ◽  
Lian Liu ◽  
Chun-hong Ma ◽  
Ji-sheng Li ◽  
Chao Du ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Cells ◽  
Ovarian Cancer Cells ◽  
Human Ovarian Cancer ◽  
Erk Pathway ◽  
E Cadherin
Sign in / Sign up

Export Citation Format

Share Document